VA/DoD CLINICAL PRACTICE GUIDELINE FOR OPIOID THERAPY FOR CHRONIC PAIN

DRAFT 3 - DO NOT DISTRIBUTE
VA/DoD Clinical Practice Guideline for Opioid Therapy for Chronic Pain
148. Graf J. Analgesic use in the elderly: The "pain" and simple truth: Comment on "the comparative
safety of analgesics in older adults with arthritis". Arch Intern Med. Dec 13 2010;170(22):1976-
1978.
149. Santos J, Alarcao J, Fareleira F, Vaz-Carneiro A, Costa J. Tapentadol for chronic musculoskeletal
pain in adults. Cochrane Database Syst Rev. 2015;5:Cd009923.
150. Schwartz S, Etropolski M, Shapiro DY, et al. Safety and efficacy of tapentadol ER in patients with
painful diabetic peripheral neuropathy: Results of a randomized-withdrawal, placebo-controlled
trial. Curr Med Res Opin. Jan 2011;27(1):151-162.
151. Vinik AI, Shapiro DY, Rauschkolb C, et al. A randomized withdrawal, placebo-controlled study
evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic
painful diabetic peripheral neuropathy. Diabetes Care. Aug 2014;37(8):2302-2309.
152. Lee JH, Lee CS. A randomized, double-blind, placebo-controlled, parallel-group study to evaluate
the efficacy and safety of the extended-release tramadol hydrochloride/acetaminophen fixeddose
combination tablet for the treatment of chronic low back pain. Clin Ther. Nov
2013;35(11):1830-1840.
153. Norrbrink C, Lundeberg T. Tramadol in neuropathic pain after spinal cord injury: A randomized,
double-blind, placebo-controlled trial. Clin J Pain. Mar-Apr 2009;25(3):177-184.
154. Schiphorst Preuper HR, Geertzen JH, van Wijhe M, et al. Do analgesics improve functioning in
patients with chronic low back pain? An explorative triple-blinded RCT. Eur Spine J. Apr
2014;23(4):800-806.
155. Steiner D, Munera C, Hale M, Ripa S, Landau C. Efficacy and safety of buprenorphine transdermal
system (BTDS) for chronic moderate to severe low back pain: A randomized, double-blind study. J
Pain. Nov 2011;12(11):1163-1173.
156. Karlsson M, Berggren AC. Efficacy and safety of low-dose transdermal buprenorphine patches (5,
10, and 20 microg/h) versus prolonged-release tramadol tablets (75, 100, 150, and 200 mg) in
patients with chronic osteoarthritis pain: A 12-week, randomized, open-label, controlled, parallelgroup
noninferiority study. Clin Ther. Mar 2009;31(3):503-513.
157. James IG, O'Brien CM, McDonald CJ. A randomized, double-blind, double-dummy comparison of
the efficacy and tolerability of low-dose transdermal buprenorphine (BuTrans seven-day patches)
with buprenorphine sublingual tablets (Temgesic) in patients with osteoarthritis pain. J Pain
Symptom Manage. Aug 2010;40(2):266-278.
158. Gordon A, Callaghan D, Spink D, et al. Buprenorphine transdermal system in adults with chronic
low back pain: A randomized, double-blind, placebo-controlled crossover study, followed by an
open-label extension phase. Clin Ther. May 2010;32(5):844-860.
159. Breivik H, Ljosaa TM, Stengaard-Pedersen K, et al. A 6-months, randomised, placebo-controlled
evaluation of efficacy and tolerability of a low-dose 7-day buprenorphine transdermal patch in
osteoarthritis patients naive to potent opioids. Scandinavian Journal of Pain.1(3):122-141.
160. Boscarino JA, Hoffman SN, Han JJ. Opioid-use disorder among patients on long-term opioid
therapy: Impact of final DSM-5 diagnostic criteria on prevalence and correlates. Subst Abuse
Rehabil. 2015;6:83-91.
161. Drug Addiction Treatment Act of 2000 (DATA 2000). Title XXXV, Section 3502, of the children’s
health act of 2000. Public Law 106-310-106th Congress.
162. Lexicomp (R). Lexicomp OnlineR, Hudson, Ohio: Lexi-Comp, Inc; 2016.
163. Bekkering GE, Soares-Weiser K, Reid K, et al. Can morphine still be considered to be the standard
for treating chronic pain? A systematic review including pair-wise and network meta-analyses.
Curr Med Res Opin. Jul 2011;27(7):1477-1491.
164. Vital signs: Risk for overdose from methadone used for pain relief - United States, 1999-2010.
MMWR Morb Mortal Wkly Rep. Jul 6 2012;61(26):493-497.
February 2017 Page 187 of 192